Organ Transplant Immunosuppressant Drugs Market Size & Share

 

Organ transplant immunosuppressant drugs are used to minimize the likelihood of organ rejection after transplantation. Immunosuppressants are drugs that lower the body's power to reject a transplanted organ. These drugs dilute the immunity system and help reduce the reaction towards the transplant. You can find two forms of immunosuppressant drugs, such as for example maintenance drugs and induction drugs. Both are antirejection drugs. Maintenance drugs are intended to use for long term, while induction drugs are utilized during the transplant.

Market Dynamics:

Increasing demand for organ transplant and the growing amount of patients in need of organ transplants is likely to propel the growth of the organ transplant immunosuppressant drugs market. For example, based on the World Health Organization (WHO), annually, around 100,800 solid organ transplants are performed over the world. Moreover, in 2018, around 36,528 transplants were performed and more than 113,000 people needed transplants at the time of January 2019, based on the U.S. Department of Health and Human Services and the Health Resources & Services Administration (HRSA).

Moreover, the increasing prevalence of chronic ailments, especially in North America, and technological advancements in organ transplants are expected to operate a vehicle the Organ Transplant Immunosuppressant Drugs Market growth. Based on the Centers for Disease Control and Prevention, around 85% of older adults have at least one chronic health condition, and around 60% have at least two chronic conditions.

Furthermore, increasing approvals of services are likely to augment the growth of the organ transplant immunosuppressant drugs market. For example, in November 2020, Lupin launched generic immunosuppressant Tacrolimus capsules in the American market following its alliance partner Concord Biotech received an approval for the merchandise from the U.S. health regulator.

Competitive Analysis:

Major players operating in the Organ Transplant Immunosuppressant Drugs Market areAstellas Pharma, Novartis AG, Accord Healthcare Ltd., Genzyme Corporation, Hoffman La Roche, Strides Pharma Global Pvt. Ltd., Panacea Biotec Ltd., Dr. Reddy's Laboratories Ltd., Veloxis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Leo Pharma, Belcher Pharmaceuticals LLC, GlaxoSmithKline Plc., Mylan Laboratories, and Watson Pharmaceuticals, Inc.

In February 2021, Creative Medical Technology Holdings, Inc. announced filing of a patent application covering the utilization of ImmCelz regenerative cell therapy for preventing rejection of transplanted organs.

In December 2020, Biocon launched Tacrolimus capsules in the United States. Tacrolimus is definitely an immunosuppressant used in treating organ transplant patients that reduces the body's power to reject a transplanted organ.